COMPASS Pathways (NASDAQ:CMPS) Trading 5.4% Higher

Shares of COMPASS Pathways plc (NASDAQ:CMPS) shot up 5.4% on Tuesday . The company traded as high as $8.55 and last traded at $8.55. 169,307 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 676,904 shares. The stock had previously closed at $8.11.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on CMPS shares. HC Wainwright reiterated a “buy” rating and issued a $120.00 price target on shares of COMPASS Pathways in a research note on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a report on Tuesday. Finally, Morgan Stanley initiated coverage on shares of COMPASS Pathways in a research report on Monday, April 1st. They issued an “overweight” rating and a $30.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat, COMPASS Pathways presently has a consensus rating of “Buy” and an average target price of $47.40.

COMPASS Pathways Trading Up 5.7 %

The stock has a market cap of $530.83 million, a price-to-earnings ratio of -3.41 and a beta of 2.48. The firm’s 50 day moving average is $9.63 and its two-hundred day moving average is $8.45. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.14.

COMPASS Pathways (NASDAQ:CMPS) last announced its earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). Equities analysts anticipate that COMPASS Pathways plc will post -2.4 EPS for the current year.

Insider Activity

In other COMPASS Pathways news, major shareholder Ekaterina Malievskaia sold 25,750 shares of the business’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $8.65, for a total value of $222,737.50. Following the transaction, the insider now owns 4,036,154 shares of the company’s stock, valued at $34,912,732.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, major shareholder George Jay Goldsmith sold 23,881 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $8.53, for a total transaction of $203,704.93. Following the completion of the transaction, the insider now directly owns 3,986,523 shares of the company’s stock, valued at approximately $34,005,041.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ekaterina Malievskaia sold 25,750 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $8.65, for a total transaction of $222,737.50. Following the transaction, the insider now directly owns 4,036,154 shares in the company, valued at $34,912,732.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 140,601 shares of company stock worth $1,338,911. Company insiders own 4.25% of the company’s stock.

Hedge Funds Weigh In On COMPASS Pathways

A number of hedge funds have recently added to or reduced their stakes in the stock. PFM Health Sciences LP increased its position in shares of COMPASS Pathways by 540.7% in the fourth quarter. PFM Health Sciences LP now owns 338,761 shares of the company’s stock worth $2,964,000 after purchasing an additional 285,890 shares during the period. Affinity Asset Advisors LLC bought a new position in COMPASS Pathways in the fourth quarter valued at about $4,812,000. Quest Partners LLC acquired a new stake in shares of COMPASS Pathways during the fourth quarter valued at about $33,000. Jump Financial LLC acquired a new stake in COMPASS Pathways during the 4th quarter worth approximately $371,000. Finally, EWA LLC bought a new stake in COMPASS Pathways during the 4th quarter worth approximately $107,000. Institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.